Please login to the form below

Not currently logged in
Email:
Password:

Takeda considers India deals, says report

India's the Economic Times has reported that Takeda is holding talks with India-based generic drug firms Cipla and Lupin

Takeda Pharmaceutical Company is reportedly in takeover talks with India-based generic drug manufacturers Cipla and Lupin, according to the Economic Times.

Takeda, which has said it wants to expand in India, one of the world's fastest growing drug markets, has reportedly held preliminary talks with Cipla, while talks with Lupin have progressed beyond the initial stage.

The newspaper, which cited individuals with direct knowledge of the development, could not confirm the story with official representatives of the companies. It did, however, quote a Cipla spokeswoman: "We would like to clarify that these reports are baseless and untrue and is categorically denied."

The Economic Times said that Takeda was interested in buying Lupin's domestic formulations business, as well as its research facility, but its founders were not willing to sell the research unit.

The speculation follows news that Sanofi is to expand its role in India with the acquisition of Universal Healthcare's over-the-counter business unit.

For more information about the fast-growing pharmaceutical industry in India, see PMGroup's Country Report: India.

24th August 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

Australian Flu and the dilemma of naming diseases
...
Wearables and Healthcare
What place do wearables have in affecting actual patient health outcomes and can they contribute to the NHS’s sustainability agenda? Or are they just the latest fad?...
What does a future-proof rep look like?
Businesses can no longer afford to push ahead with the traditional Key Account Management model....

Infographics